Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma
Status:
Withdrawn
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
There have been reports suggesting that anti-epidermal growth factor antibody nimotuzumab is
advantageous for advanced esophageal cancer patients in combination with chemotherapy or
radiotherapy.And,albumin-bound paclitaxel was characterized with high tolerated doses with
greater efficacy,and with greater concentration in tumor tissue compared with normal
tissues.So,The objective of this single-arm phase II trial was to evaluate the benefit of
nimotuzumab plus nab-paclitaxel and cisplatin in patients with advanced esophageal carcinoma.